Walleye Capital’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Walleye Capital’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-36,469	Closed	-$478	–	5875
2024 Q3	$478	Hold	36,469	–	–	﹤0.01%	5165
2024 Q2	$1.53K	Hold	36,469	–	–	﹤0.01%	5448
2024 Q1	$1.9K	Hold	36,469	–	–	﹤0.01%	5270
2023 Q4	$1.82K	Hold	36,469	–	–	﹤0.01%	4771
2023 Q3	$8.02K	Hold	36,469	–	–	﹤0.01%	4508
2023 Q2	$4.74K	Hold	36,469	–	–	﹤0.01%	4033
2023 Q1	$1.5K	Hold	36,469	–	–	﹤0.01%	3812
2022 Q4	$1.82K	Hold	36,469	–	–	﹤0.01%	3000
2022 Q3	$2K	Buy	36,469 +4,940	+16%	+$297	﹤0.01%	3071
2022 Q2	$3K	Hold	31,529	–	–	﹤0.01%	2210
2022 Q1	$11K	Hold	31,529	–	–	﹤0.01%	2081
2021 Q4	$16K	Buy	+31,529	New	+$17.8K	﹤0.01%	1973

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Walleye Capital's CLDI.WS Position: Q4 2024 in Review

Walleye Capital sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 36,469 shares — an estimated $478 sold.

Walleye Capital first reported a position in CLDI.WS in Q4 2021 and held it in 12 quarters. The position peaked at $16K in Q4 2021. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Walleye Capital reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Walleye Capital sold 36,469 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $478.
Walleye Capital first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 12 quarters.
Walleye Capital's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $16K in Q4 2021.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.